- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
EN
R
RLMD
Relmada Therapeutics Inc
6.93
+0.18+2.67%Opening13:20 04/08 EDT
OPEN/PREV CLOSE7.00/6.75
TODAY RANGE6.84-7.07
VOL331.29K
MARKET CAP726.89M
52 WEEK RANGE0.2430-7.51
AVG VOL (3M)1.60M
% TURNOVER0.32%
TURNOVER--
P/E (TTM)-4.7678
% RANGE3.33%
EPS(TTM)-1.4535
P/E(FORWARD)-8.8846
P/B5.87
BVPS1.180
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP434.89M
SHARES OUTSTANDING104.89M
NEXT EARNINGS05/11-05/15
FREE FLOAT62.75M
LOT SIZE1
EX-DATE09/30/2019
News
Press Releases
Financial Reports
Profile
TipRanks·15h ago
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)
Seeking Alpha·03/30 19:16
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See
Reuters·03/30 07:01
PreveCeutical appoints Dr. Raj S. Pruthi to board of directors
Seeking Alpha·03/24 18:31
Relmada wins bullish view at Piper Sandler on cancer therapy
Dow Jones·03/24 13:05
Relmada Therapeutics Price Target Announced at $12.00/Share by Piper Sandler
TipRanks·03/24 09:00
Relmada Therapeutics initiated with an Overweight at Piper Sandler
Reuters·03/24 07:39
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
TipRanks·03/21 00:05
Relmada Therapeutics Charts Aggressive Path After Earnings Call
TipRanks·03/20 21:21
Relmada Highlights NDV-01 Data, Funding in 2025 Results
Dow Jones·03/20 13:54
Relmada Therapeutics Price Target Raised to $19.00/Share From $10.00 by Mizuho
Dow Jones·03/20 13:54
Relmada Therapeutics Is Maintained at Outperform by Mizuho
Benzinga·03/20 13:44
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19
Same Industry
Name/Symbol
Change%
Price